EGFR and head and neck squamous cell carcinoma: It is against this background that at least five sets of consensus recommendations have been published8,9,29–31, together with expert opinions and recommendations for the treatment of the skin toxicities associated with EGFR-targeted therapies in general12,19,26,33,34, and the radiation dermatitis seen in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) receiving cetuximab concomitantly with radiotherapy35, in particular.